Gracell Biotechnologies Inc. American Depositary Shares
GRCL
GRCL was delisted on the 21st of February, 2024.
33 hedge funds and large institutions have $98.3M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 32 → 33 (+1)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
44% less capital invested
Capital invested by funds: $176M → $98.3M (-$77.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.46M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$80.2K |
| 3 |
CII
Capital International Inc
Los Angeles,
California
|
+$73.8K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$39.8K |
| 5 |
CC
Cannell Capital
Alta,
Wyoming
|
+$39.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$4.31M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.88M |
| 3 |
Morgan Stanley
New York
|
-$1.07M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$720K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$681K |
GRCL Hedge Fund Activity: Q3 2022 in Review
33 institutional investors reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q3 2022, worth a combined $98.3M — down 44% from $176M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GRCL positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $1.46M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $4.31M sold.
- 33 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q3 2022, up from 32 in Q2 2022.
- Funds reported $98.3M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q3 2022, down 44% quarter-over-quarter.
- 5 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q3 2022 and 4 closed out, a net change of +1 holder.
- The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q3 2022 was Great Point Partners, an estimated $1.46M added.
- The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q3 2022 was Paradigm Biocapital Advisors, an estimated $4.31M sold.
Based on aggregated 13F filings for Q3 2022.